The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2603-2616

  Fernández Suárez, Diana ^a,g   Celorrio, Marta ^a   Riezu Boj, José Ignacio ^a   Ugarte, Ana ^a   Pacheco, Rodrigo ^b,c   González, Hugo ^b   Oyarzabal, Julen ^a   Hillard, Cecilia J ^d   Franco, Rafael ^a,e   Aymerich, María S ^a,f  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Fundacion Ciencia para la Vida   (Chile)

^c UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Astroglia; Endocannabinoid system; JZL184; Microglia; Monoacylglycerol lipase; Neuroprotection; Parkinson's disease

Indexed keywords

4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; BETA CATENIN; MESSENGER RNA; WNT PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ACYLGLYCEROL LIPASE; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; GLIAL FIBRILLARY ASTROCYTIC PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PROBENECID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GLIA CELL; MACROGLIA; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PHENOTYPE; PROTEIN TRANSPORT; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CORPUS STRIATUM; DISEASE MODEL; GLIA; METABOLISM; NERVE TRACT; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION (PROCESS); SUBSTANTIA NIGRA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; BENZODIOXOLES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GLYCERIDES; MALE; MICE, INBRED C57BL; MONOACYLGLYCEROL LIPASES; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PIPERIDINES; PROBENECID; SUBSTANTIA NIGRA;

EID: 84922880383     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.05.021     Document Type: Article

References (74)

1. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E.C., Hartmann A., Michel P.P. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J.Neurochem. 2008, 107:701-711.
2. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12:25-31.
3. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
4. Boche D.P.V., Nicoll J.A. Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 2013, 39:3-18.
5. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 2003, 3:54-61.
6. Busquets-Garcia A., Puighermanal E., Pastor A., de la Torre R., Maldonado R., Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiatry 2011, 70:479-486.
7. Compton D.R., Aceto M.D., Lowe J., Martin B.R. Invivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J.Pharmacol. Exp. Ther. 1996, 277:586-594.
8. Chhatwal J.P., Davis M., Maguschak K.A., Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005, 30:516-524.
9. Czeh M., Gressens P., Kaindl A.M. The yin and yang of microglia. Dev. Neurosci. 2011, 33:199-209.
10. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000, 14:1432-1438.
11. Drojdahl N., Nielsen H.H., Gardi J.E., Wree A., Peterson A.C., Nyengaard J.R., Eyer J., Finsen B. Axonal plasticity elicits long-term changes in oligodendroglia and myelinated fibers. Glia 2010, 58:29-42.
12. Fernandez-Espejo E., Caraballo I., de Fonseca F.R., El Banoua F., Ferrer B., Flores J.A., Galan-Rodriguez B. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 2005, 18:591-601.
13. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156:1029-1040.
14. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
15. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 1993, 231:313-314.
16. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J.Neurosci. 2004, 24:1865-1872.
17. Gaetani S., Cuomo V., Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs?. Trends Mol. Med. 2003, 9:474-478.
18. Garbayo E., Ansorena E., Lanciego J.L., Blanco-Prieto M.J., Aymerich M.S. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease. Mov. Disord. 2011, 26:1943-1947.
19. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
20. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cellline-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
21. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999, 2:358-363.
22. Gong D., Shi W., Yi S.J., Chen H., Groffen J., Heisterkamp N. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012, 13:31.
23. Gonzalez H., Contreras F., Prado C., Elgueta D., Franz D., Bernales S., Pacheco R. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J.Immunol. 2013, 190:5048-5056.
24. Gonzalez S., Scorticati C., Garcia-Arencibia M., de Miguel R., Ramos J.A., Fernandez-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 2006, 1073-1074:209-219.
25. Gordon M.D., Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J.Biol. Chem. 2006, 281:22429-22433.
26. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A., Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J.Neurosci. 2002, 22:6900-6907.
27. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J.Microsc. 1987, 147(Pt 3):229-263.
28. Hurley M.J., Mash D.C., Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J.Neural Transm. 2003, 110:1279-1288.
29. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
30. Lanciego J.L., Barroso-Chinea P., Rico A.J., Conte-Perales L., Callen L., Roda E., Gomez-Bautista V., Lopez I.P., Lluis C., Labandeira-Garcia J.L., Franco R. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J.Psychopharmacol. 2011, 25:97-104.
31. Larsen J.O., Gundersen H.J., Nielsen J. Global spatial sampling with isotropic virtual planes: estimators of length density and total length in thick, arbitrarily orientated sections. J.Microsc. 1998, 191:238-248.
32. Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 2001, 14:1827-1832.
33. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity invivo and invitro: relevance to Parkinson's disease. Neurobiol. Dis. 2005, 19:96-107.
34. Lau Y.S., Crampton J.M., Wilson J.A. Urinary excretion of MPTP and its primary metabolites in mice. Life Sci. 1988, 43:1459-1464.
35. Lau Y.S., Trobough K.L., Crampton J.M., Wilson J.A. Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 1990, 21:181-187.
36. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Cossetti C., D'Adamo P., Zardini E., Andreoni L., Ihekwaba A.E., Serra P.A., Franciotta D., Martino G., Pluchino S., Marchetti B. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 2011, 41:508-527.
37. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
38. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
39. Long J.Z., Nomura D.K., Vann R.E., Walentiny D.M., Booker L., Jin X., Burston J.J., Sim-Selley L.J., Lichtman A.H., Wiley J.L., Cravatt B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk invivo. Proc. Natl. Acad. Sci. U.S.A 2009, 106:20270-20275.
40. Luchtman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 2009, 98:130-138.
41. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
42. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
43. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
44. Meredith G.E., Rademacher D.J. MPTP mouse models of Parkinson's disease: an update. J.Parkinsons Dis. 2011, 1:19-33.
45. Meredith G.E., Totterdell S., Beales M., Meshul C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp. Neurol. 2009, 219:334-340.
46. Meschler J.P., Howlett A.C., Madras B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 2001, 156:79-85.
47. Mesnage V., Houeto J.L., Bonnet A.M., Clavier I., Arnulf I., Cattelin F., Le Fur G., Damier P., Welter M.L., Agid Y. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol. 2004, 27:108-110.
48. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J.Neurosci. 1999, 19:2987-2995.
49. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
50. Oderup C., Lajevic M., Butcher E.C. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. J.Immunol. 2013, 190:6126-6134.
51. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
52. Paxinos G., Franklin K.B.J. The Mouse Brain in Sterotaxic Coordinates 2001, Academic Press.
53. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
54. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agro A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P., Maccarrone M. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 2005, 57:777-779.
55. Pisani V., Madeo G., Tassone A., Sciamanna G., Maccarrone M., Stanzione P., Pisani A. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov. Disord. 2010, 26:216-222.
56. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernandez E., Strong R., Lutz B., Marsicano G., Roberts J.L., Giuffrida A. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:2177-2186.
57. Romero J., Berrendero F., Perez-Rosado A., Manzanares J., Rojo A., Fernandez-Ruiz J.J., de Yebenes J.G., Ramos J.A. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 2000, 66:485-494.
58. Romero J., Garcia-Palomero E., Fernandez-Ruiz J.J., Ramos J.A. Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav. Pharmacol. 1996, 7:299-302.
59. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 2006, 23:533-542.
60. Sanudo-Pena M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 1998, 248:171-174.
61. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
62. Shao W., Zhang S.Z., Tang M., Zhang X.H., Zhou Z., Yin Y.Q., Zhou Q.B., Huang Y.Y., Liu Y.J., Wawrousek E., Chen T., Li S.B., Xu M., Zhou J.N., Hu G., Zhou J.W. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. Nature 2013, 494:90-94.
63. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J.Neurosurg. 2005, 102:216-222.
64. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
65. Tompkins M.M., Basgall E.J., Zamrini E., Hill W.D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 1997, 150:119-131.
66. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., Brotchie J.M. Arole for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 2005, 19:1140-1142.
67. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
68. Walter L., Neumann H. Role of microglia in neuronal degeneration and regeneration. Semin. Immunopathol. 2009, 31:513-525.
69. Wang M., Hill M.N., Zhang L., Gorzalka B.B., Hillard C.J., Alger B.E. Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J.Psychopharmacol. 2012, 26:56-70.
70. Wiley J.L., Martin B.R. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur. J. Pharmacol. 2003, 471:185-193.
71. Wirjatijasa F., Dehghani F., Blaheta R.A., Korf H.W., Hailer N.P. Interleukin-4, interleukin-10, and interleukin-1-receptor antagonist but not transforming growth factor-beta induce ramification and reduce adhesion molecule expression of rat microglial cells. J.Neurosci. Res. 2002, 68:579-587.
72. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
73. Yasuhara T., Matsukawa N., Hara K., Yu G., Xu L., Maki M., Kim S.U., Borlongan C.V. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J.Neurosci. 2006, 26:12497-12511.
74. Yasuhara T., Shingo T., Muraoka K., Kameda M., Agari T., Wen Ji Y., Hayase H., Hamada H., Borlongan C.V., Date I. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 2005, 1053:10-18.